Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing
| Class:Id | LiteratureReference:5685577 |
|---|---|
| _displayName | A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing |
| _timestamp | 2015-03-27 14:08:43 |
| author | [Person:5685573] Hernández-Caselles, Trinidad [Person:5685562] Martínez-Esparza, María [Person:5685543] Pérez-Oliva, Ana B [Person:5685541] Quintanilla-Cecconi, Ana M [Person:5685561] García-Alonso, Ana [Person:5685550] Alvarez-López, D María Rocío [Person:5685544] García-Peñarrubia, Pilar |
| created | [InstanceEdit:5685547] Garapati, Phani Vijay, 2015-03-27 |
| journal | J. Leukoc. Biol. |
| pages | 46-58 |
| pubMedIdentifier | 16380601 |
| title | A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing |
| volume | 79 |
| year | 2006 |
| (literatureReference) | [Reaction:5685607] Sialic acid binds SIGLEC [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing (5685577)
